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Background: Stroke has a huge impact, leaving more than a third of affected people with lasting disability and
rehabilitation remains a cornerstone treatment in the National Health Service (NHS). Recovery of mobility and arm
function post-stroke occurs through re-learning to use the affected body parts and/or learning to compensate with
the lesser affected side. Promising evidence suggests that the addition of Co-careldopa to physical therapy and
occupational therapy may improve the recovery of arm and leg movement and lead to improved function.
Methods/design: Dopamine Augmented Rehabilitation in Stroke (DARS) is a multi-centre double-blind, randomised,
placebo, controlled clinical trial of Co-careldopa in addition to routine NHS occupational therapy and physical therapy
as part of early stroke rehabilitation. Participants will be randomised on a 1:1 basis to either Co-careldopa or placebo.
The primary objective of the trial is to determine whether the addition of six weeks of Co-careldopa treatment to
rehabilitation therapy can improve the proportion of patients who can walk independently eight weeks
post-randomisation.
Discussion: The DARS trial will provide evidence as to whether Co-careldopa, in addition to routine NHS occupational
and physical therapy, leads to a greater recovery of motor function, a reduction in carer dependency and advance
rehabilitation treatments for people with stroke.
Trial registration: ISRCTN99643613 assigned on 4 December 2009.
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Stroke is the most common cause of severe disability
(annual UK incidence of first stroke is 100,000). Stroke
has a huge impact, leaving more than a third of affected
people with lasting disability affecting selfcare. One year
after a stroke 31% of survivors are still dependent for
outside mobility and 15% are dependent for inside mo-
bility. The number of disabled stroke survivors will in-
crease due to ageing population demographics. The cost* Correspondence: s.hartley@leeds.ac.uk
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unless otherwise stated.of stroke accounts for 6% of the total National Health
Service (NHS) and social services expenditures. Al-
though acute stroke interventions, such as thrombolysis,
can reduce mortality and morbidity, rehabilitation re-
mains the cornerstone treatment within the NHS for the
majority of people with stroke.
The role of high quality rehabilitation within compre-
hensive stroke services is widely acknowledged as de-
scribed by the English National Stroke Strategy. Despite
the clear benefits of organised stroke care at least 30,000
people in the UK each year are left with physical disabil-
ity, increasing the long term societal costs of dependencyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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those individuals and their families. Despite the clear
benefits of organised stroke care, a third of people with
stroke are left with significant physical disabilities. Physical
and occupational therapies have been shown to benefit
people but residual disability for a large proportion
of patients still remains a key issue in regaining full
independence.
Learning is an essential process by which recovery of
mobility and arm function occurs after stroke, either
through relearning to use the affected body parts and/or
learning to compensate with the lesser affected side (for
example, one-handed dressing). These situations involve
the patient becoming attuned to the perceptions which
guide skilled movement, such as vision and propriocep-
tion. At a clinical level, the patient practises motor
skills with guidance and support from therapists [1]. At
a biological level, this practice leads to changes in be-
haviour (learning) through functional re-organization
of the central nervous system (CNS) by a process of
neural plasticity [2].
Pharmacological priming of the brain and motor skill
acquisition: The emerging evidence from pilot studies
indicates that the addition of certain drugs with physical
and occupational therapy may improve the recovery of
arm and leg movements and, thus, recovery of essential
day to day activities such as walking and getting dressed.
These improvements are in addition to the benefits gained
from physiotherapy and occupational therapy alone. These
studies suggest that the nerve circuits in the brain respond
better to the usual therapy when they are also exposed
to drugs such as dopamine at the same time as having
occupational or physiotherapy.
Evidence from animal and human studies indicates an
important role of noradrenergic/dopaminergic brain
pathways in motor skill acquisition [3,4]. Animal studies
demonstrate that neural plasticity comprises cellular
processes (for example, changes in synaptic morphology,
synaptic potentiation/depression, dendrite sprouting and
alteration of axonal trajectories [5]). Involvement of adren-
ergic neurotransmitters in these processes raises the possi-
bility of pharmacologically promoting neural plasticity by
increasing catecholamine levels in the CNS (for example,
oral amphetamine increases the brain levels of dopamine,
serotonin and norepinephrine) which can modulate long-
term changes in synaptic function. Studies in rats suggest
that amphetamines can promote relearning after experi-
mental brain injury [6]. Encouraged by this evidence, sev-
eral clinical trials of amphetamines in stroke patients have
been undertaken. A Cochrane review of 12 small clinical
trials (344 patients) reported a trend towards improved
motor function [7] and suggested that further studies to
confirm an effect on motor recovery were warranted.
There is no evidence of increased mortality/dependencywith amphetamine administration in stroke patients.
However, adverse sympathomimetic effects with am-
phetamines, such as tachycardia and hypertension, are
reported.
A growing body of evidence suggests that learning and
motor skill acquisition occurs through the dopaminergic
system rather than through direct noradrenergic action
of general arousal. Therefore, drugs that promote dopa-
minergic activity directly may be more appropriate as
targeted brain modulators [8] in the context of motor
skill acquisition and be associated with fewer adverse
cardiovascular effects. Levodopa (L-dopa) is a precursor
of dopamine which crosses the blood–brain barrier and
is converted to dopamine in the brain. Co-careldopa is a
routinely available inexpensive medication that will be
used to deliver 100 mg of levodopa through its com-
bination with 25 mg carbidopa. Co-careldopa is used
to deliver L-dopa as this contains carbidopa, a periph-
eral dopa-decarboxylase inhibitor which reduces the
peripheral adverse effects of levodopa. The peak effect
is 0.5 to 2 hours after an oral dose and plasma half-life
is 1 to 3 hours.
The impact of L-dopa on motor function in stroke has
been investigated in small scale clinical studies taking
into account the temporal linkage between drug adminis-
tration and physical therapy treatment [9]. This random-
ized controlled trial (RCT) reported the effect of L-dopa
(oral co-careldopa – 100 mg Levodopa/25 mg carbidopa)
on motor function in 53 people who were three weeks
to six months post stroke. All patients received daily
physiotherapy sessions lasting 30 minutes for three
weeks in a hospital setting. Motor function was assessed
using the Rivermead Mobility Index (RMI). Significantly
greater improvement in RMI scores and walking ability
were reported in the L-dopa treated group compared
with placebo. The drug was well tolerated and no ser-
ious drug related adverse events were reported. The
effect on function was still present three weeks after
cessation of L-dopa. Although these results are encour-
aging, the study has a number of limitations [10] includ-
ing sample size and the recruitment of some patients in
the post acute phase of stroke when effects on neuro-
plasticity may be less.
Rationale for the clinical trial: In this trial we will find
out if the addition of Co-careldopa (a widely available
and inexpensive form of the drug that is commonly used
to treat Parkinson’s Disease) to routine NHS occupa-
tional and physical therapy enhances the effect of the
therapy and further improves recovery of functionally
useful arm and leg movement in people with new or re-
current clinically diagnosed stroke. The dose and timing
of the medication within this trial reflects current evi-
dence on the use of L-dopa in this context [9,11-13]. All
study participants will receive usual stroke care within
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study drug will be used in addition to conventional re-
habilitation treatment, including at home if rehabilitation
treatment continues after discharge from hospital, up to a
maximum of six weeks and no more than twice per day.
Those potentially suitable to take part in this study will
be identified on admission to hospital with stroke, and
eligibility will be confirmed between day 5 and day 42
post-stroke.
Methods/design
Objectives
The primary objective relates to physical functioning
and will compare the proportion of patients between
treatment groups who are walking independently at
eight weeks post-randomisation (as measured by a score
of 7 or higher and who also answer ‘yes’ to item number
7 on the RMI).
Secondary objectives are to determine: (1) the impact
on physical functioning and mood at eight weeks, six
months and twelve months; (2) potential moderators and
mediators of effect at eight weeks, six months and twelve
months; (3) implementation within routine healthcare
services; and (4) the cost-effectiveness of co-careldopa
augmented rehabilitation for stroke compared to usual
care within stroke services.
(1) Investigation of impact on physical functioning and
mood at eight weeks, six months and twelve months
 To compare the proportion of patients who are
walking at six and twelve months post-
randomisation between the groups (as measured
by a score of 7 or higher on the RMI and who
also answer yes on item number 7)
 To compare activities of daily living, mobility and
dependency using the RMI (continuous), Barthel
Index, Modified Rankin Scale, Nottingham
Extended Activities of Daily Living (NEADL)
scale and ABILHAND between groups.
 To compare psychological distress/mood between
groups using the General Health Questionnaire
12 (GHQ-12)
 To compare carer burden between groups using
the Caregiver Burden Scale (CBS)
(2) Investigate potential moderators and mediators of
effect at eight weeks, six months and twelve months
 To investigate whether baseline patient clinical
characteristics and investigations (for example,
routine brain CT scanning) help to predict those
who might benefit from Co-careldopa augmented
rehabilitation
 To investigate whether key factors (for example,
fatigue measured by the Fatigue Assessment Scale
(FAS)), concurrent musculoskeletal symptoms,signs and pain (using the MSK SSP manikin) and
cognitive function (using the Montreal Cognitive
Assessment (MoCA)) influence the short and
long term effect of Co-careldopa on physical
functioning
(3) Investigation of implementation within NHS
 To assess the adverse event profile associated
with Co-careldopa in addition to conventional
NHS stroke rehabilitation treatment
 To investigate the practical implications of
delivering this combined intervention within
routine NHS acute and early community care of
people with stroke
 To assess the acceptability of Co-careldopa
treatment to stroke patients (study drug
adherence will be measured)
(4) To determine the cost-effectiveness of Co-careldopa
versus placebo for rehabilitation after stroke
Trial design
DARS is a multi-centre, prospective, randomised, double-
blinded, placebo controlled trial of NHS physical therapy
and occupational therapy treatment alone compared to
NHS physical therapy and occupational therapy treatment
with six weeks of Co-careldopa treatment for those admit-
ted to acute stroke services after new or recurrent stroke.
A total of 572 people with stroke admitted to acute
stroke services will be recruited. Each participant will be
randomised to receive either Co-careldopa or placebo for
six weeks post stroke. Routine NHS therapy will continue
according to normal practice.
Outcome measures will be obtained at eight weeks, six
months and twelve months following randomisation. The
blinded design in which participants, treating clinicians
and trial personnel will be blinded to group allocation will
minimise bias by ensuring that Co-careldopa related
intervention effects and information collection is the
same between the active drug and placebo groups. Fur-
ther minimisation of bias and maximising masking will
be ensured by appropriate placebo and Co-careldopa
preparation, blinding both patients and clinicians. Out-
comes will be collected by assessors masked to the
treatment allocation. All analyses will be undertaken
blinded to treatment allocation until final analysis.
The National Research Ethics Service and the Medicines
and Healthcare Products Regulatory Agency have ap-
proved this trial. Trial participants will be recruited
from acute and community stroke services across more
than 50 centres. Written informed consent will be ob-
tained from all participants.
Setting
The trial will take place in stroke services with access to
continuity of rehabilitation treatment following discharge
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Discharge or hospital/community therapy according to
local practice.
Inclusion criteria
1. New or recurrent clinically diagnosed ischaemic or
haemorrhagic (excluding subarachnoid
haemorrhage) stroke within 5 to 42 days prior to
randomisation.
2. Cannot walk 10 metres or more indoors
independently (that is, without use of physical
assistance)
3. Rivermead Mobility Index score of <7.
4. Expected to need rehabilitation treatment
5. Aged 18 years or above
6. Able to give informed consent
7. Able to access continuity of rehabilitation treatment
following discharge from hospital which is available
within five days following hospital discharge.
8. Expected to be able to comply with the treatment
schedule (for example, swallow whole tablets)
9. Expected to be in hospital for at least the first two
doses of trial medication
Exclusion criteria
Patients meeting any of the following criteria are not
eligible for trial entry.
1. Not expected to survive for two months following
stroke
2. Diagnosis of Parkinson’s disease, severe medical or
surgical illness, severe psychosis
3. Known hypersensitivity or contraindications to
Co-careldopa
4. Symptomatic orthostatic hypotension
5. Needed physical assistance of at least one person to
walk prior to stroke due to pre-existing
co-morbidities (for example, heart failure,
osteoarthritis)
6. Pregnancy, lactation or women of child-bearing
potential unwilling to use medically approved
contraception whilst receiving treatment and for one
month after treatment has finished
7. Could not walk 10 metres or more indoors prior to
their stroke (may have used a walking aid if
necessary, but required no physical assistance). In
this context physical assistance means help from one
or more persons.
Recruitment and randomisation
Patients admitted to stroke services after a new or recur-
rent stroke will be identified on admission to the stroke
unit and considered for enrolment from day 5 to day 42post stroke. Patients with aphasia will be given informa-
tion in a manner that can be easily understood and,
where practical, arrangements are made to meet the pa-
tient’s language, communication and other support
needs. Patients who are initially ineligible for the trial
due to other co-morbidities (for example, swallowing
difficulties, lack of capacity to give informed consent)
may subsequently become eligible. They will continue to
be monitored until 42 days post stroke to determine if
their condition improves and they consequently become
eligible for the trial (refer to Figure 1: Patient Recruit-
ment Pathway).
Informed written consent will be obtained from all
participants and will also be sought from carers (if
present) to allow information relating to carer burden
to be collected.
Participants who fulfil the eligibility criteria will be
randomised on a 1:1 basis to receive either Co-careldopa
or placebo. Stratified randomisation will be used to en-
sure that treatment groups are well-balanced for: (1)
recruiting centre; (2) type of stroke (primary intracranial
haemorrhage; infarct); and (3) RMI score 0–3; >3 but
<7.
Blinding
Patients, clinicians, site research staff and trial personnel
at the Clinical Trials Research Unit (CTRU) involved in
the day-to-day running of the trial will be blinded to
group allocation until the final database lock. A matched
placebo has been manufactured to match the commercial
Co-careldopa. Final assembly, packaging and labeling of
the Co-careldopa/placebo kit is performed by an inde-
pendent clinical supplies company. Each kit is labeled and
identified by a unique random five digit number only. A
trial safety team will have access to the treatment alloca-
tion for the purposes of emergency unblinding and prep-
aration of unblinded reports to the Data Monitoring and
Ethics Committee.
Intervention
Patients will take a single oral tablet 45 to 60 minutes
before routine NHS physical or occupational therapy
sessions for a maximum of six weeks. Routine physical
or occupational therapy is defined as active physical
treatment (that is, most physical and occupational ther-
apy directed at motor skills, such as walking, transfers,
and dressing but not solely psychological input sessions
or speech and language therapy). This also includes
programmed rehabilitation delivered by rehabilitation
assistants.
The dose and timing of the medication reflects current
evidence on use of Co-careldopa in this context (9, 11,
12, 13). As part of this trial a pragmatic approach will be
taken. Although the dose should be taken optimally
*Inclusion criteria 6, 8 and other co morbidities should be monitored up to 42 days post stroke as patients initially not 
meeting the eligibility criteria may improve within the 42 days post stroke.
Weekly 
screening up to 
end of 
recruitment
Eligible
Ineligible
Consider Carer participation 
and consent if appropriate
Return Screening Form
Patients with new or 
recurrent stroke
CONSIDER ELIGIBILITY & SCREEN
(Screen from Day 0; confirm eligibility from Day 5 –42)
Eligible Ineligible*
Discuss trial 
participation ASAP and 
provide Information 
Sheet
Obtain written 
informed consent
Complete                    
baseline assessments and 
randomise
First 2 doses administered as 
inpatient at ½ strength in hospital
Drug therapy continues in hospital 
or in community setting for up to 
6 weeks, maximum of twice per day
Follow up in patient’s homes
At 8 weeks (primary end point),
6 months and 12 months
post randomisation
Patient questionnaires and 
therapist 
CRF completion
Day 0
Up to 
day 42
≥24 hours
Decline
Day 5 
Figure 1 Patient recruitment pathway.
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treatment session it is recognised that there may be occa-
sions where, for example, the therapist is unable to contact
the patient to remind them to take the tablet or the pa-
tient may forget. It is acceptable for the tablet to be taken
within 0 to 15 minutes before the start of therapy in these
situations. The peak effect of Co-careldopa is 0.5 to
2 hours after an oral dose. If the patient is scheduled to
have two therapy sessions directly one after the other or
within three hours of a dose then a repeat dose is not
given before the second of the therapy sessions. If the pa-
tient is having more than two physical or occupational
therapy sessions, the dose will not be administered more
than twice during any one 24 hour period.Assuming a maximum of two sessions of physiotherapy
(PT) or occupational therapy (OT) per day for 30 days
over a six week treatment period, each patient will receive
a maximum of 60 tablets during their participation in the
intervention phase of the trial. Investigational Medicinal
Product (IMP) with usual NHS rehabilitation treatments
will be continued for a maximum of six weeks as long
as it is deemed that the patient would benefit from on-
going rehabilitation. The duration of treatment may be
less if the patient is clinically deemed not to require fur-
ther rehabilitation treatment. The decision about need
for rehabilitation interventions (when to start, finish
and type) will be made by the treating clinicians, thera-
pists and nurses in consultation with patients and
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patient (refer to Figure 2: Patient treatment scenarios).
In both treatment arms, clinicians and therapists receive
the same instructions with regards to need for interven-
tions. The trial is blinded, ensuring both treatment
groups receive the same amount of attention from clini-
cians and therapists. As part of the analysis we also as-
sess the level of blinding by calculating blinding index
for each treatment group.
The IMP will be first administered in an inpatient
stroke unit after the patient has consented and been ran-
domised. The first two doses of Co-careldopa will be
62.5 mg (Levodopa 50 mg and carbidopa 12.5 mg) and
the remaining doses will be 125 mg (Levodopa 100 mg
and carbidopa 25 mg) and will be administered in hospital.
The participating site will, therefore, be able to closely ob-
serve patients for any early adverse events occurring as a
result of the trial IMP. The patient will be assessed by the
stroke unit nursing staff (prior to discharge from hospital)
as to his/her ability to self-medicate (in relation to the
IMP) after discharge from hospital. Once discharged from* Rehabilitation treatment appropriate for drug ad
physical treatment (i.e. most physical and occupatio
transfers and dressing, but not psychological input s
splin
Study dru
Randomisation
Treatment 
day 1
6 weeks 
max
Study drug taken 
45–60 minutes 
prior to each 
rehab treatment* 
session (whether 
in-patient or 
community 
rehab)
Scenario A
In-patient 
rehabilitation
Figure 2 Patient treatment scenario.hospital (if prior to completion of the six-week course of
IMP) the trial intervention will be continued at home
or other discharge destination. Telephone reminders
approximately one hour prior to a therapy visit will be
provided by treating community rehabilitation staff to
prompt the patient to take the trial medication prior to
the community rehabilitation session. At the start of
the therapy session, the rehabilitation staff will ask the
patient if they have taken the IMP and what time the
IMP was taken. The timing and content of the PT/OT
session is recorded by the treating therapist. Where
IMP has not been taken, it is recommended that the
dose is taken as soon as the therapist arrives.Outcomes
The primary outcome will assess whether patients can
walk independently at eight weeks post-randomisation as
measured by a RMI score of 7 or higher and can walk 10
metres with an aid if necessary but with no standby help
(that is, answer ‘yes’ to item number 7 on the RMI).ministration within DARS is defined as an active
nal therapy directed at motor skills such as walking, 
essions or speech and language therapy, swallowing, 
ting).
g stops
Scenario B
Community 
Stroke Team 
rehabilitation
In-patient 
rehabilitation
Scenario C
Community 
Stroke Team 
rehabilitation
Patient 
discharged from 
rehabilitation
Study drug 
stops
In-patient 
rehabilitation
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weeks, six and twelve months):
 Physical functioning: RMI (continuous), Barthel
Index (dependency measure), Modified Rankin
Scale, NEADL scale (extended activities of daily
living), ABILHAND (bilateral arm activities)
 Mood: GHQ-12
 Potential moderators and mediators of treatment
effect: baseline clinical characteristics and
investigations (for example, routine brain
neuroimaging) will be collected to predict those who
might benefit from Co-careldopa augmented
rehabilitation; fatigue (FAS)), concurrent
musculoskeletal symptoms, signs and pain (using the
MSK SSP manikin) and cognitive function (using the
MoCA).
 Implementation within NHS: to investigate the
practical implications of delivering this intervention
within routine NHS acute and early community care
of people with stroke; and to assess acceptability of
Co-careldopa treatment to stroke patients through
measuring study drug adherence will be undertaken
with participants at the week 8 assessment.
Process outcomes: Standardised therapy forms will be
used to document the type of rehabilitation received by
the trial participant. These logs will also capture infor-
mation ease of compliance with timing of treatment
schedule, IMP packaging, clarity of instructions and
labelling.
Carer outcomes: The CBS will be administered at eight
weeks, six and twelve months to assess carer outcomes.
Safety: Adverse events, whether volunteered by the pa-
tient or carer, or identified by the therapist or researcher,
until the eight week follow up appointment are docu-
mented. As an inpatient, the local research team will
monitor the patient for the occurrence of adverse events.
Following discharge from hospital, detection of most ad-
verse events will occur through spontaneous reporting
by patients, their carers, attending therapists or via the
scheduled visits by the researcher. Serious adverse events
(SAEs) will be reported to the CTRU up to 30 days after
the last dose of protocol treatment. All serious unex-
pected suspected adverse reactions (SUSARs) are re-
ported to the CTRU within 24 hours and expedited
reported to the MHRA, ethics committee and Sponsor
where applicable.
Health economics: Patient NHS resource use data
(contact with primary, community and social care ser-
vices together with hospital admissions and out-patient
visits) will be collected along with EQ-5D health state
utilities at baseline, eight weeks and at six and twelve
months. Carers will also complete a resource usemeasure and the EQ-5D to respectively capture the costs
and quality of life impact of providing care.
Assessments:
Patient outcomes at all follow-up time points (eight
weeks, six and twelve months) will be collected via inter-
view by the independent researcher in the patient’s home
or at the hospital or community facility (refer to Table 1
Schedule of Events).
Sample size
We plan to recruit 572 patients from more than 50 hos-
pitals across the UK. This will provide 90% power at 5%
significance to detect 50% relative difference between
the placebo and active treatment group in the proportion
walking independently at eight weeks post randomisation
(as measured by the RMI score 7 or greater and who also
answer ‘yes’ to item number 7). This assumes the same
control rate of 26% as in the Scheidtmann study [9]
and will ensure the minimum improvement that can be
detected is 39% of patients on active treatment who are
walking independently by eight weeks.
The primary intention to treat (ITT) analysis will
include all randomised patients as it will assume that
patients who die or are lost to follow-up are unable
to walk independently.
This sample size also provides 80% power to detect a
small to moderate effect size of 0.3 in key secondary out-
comes (for example, ABILHAND - to measure functional
upper limb activities; the NEADL scale measuring instru-
mental activities of daily living, such as outdoor mobility
and household tasks). It is important that the study has
sufficient power to detect real change in these secondary
outcomes given that they are (1) important functional
parameters in addition to walking and (2) are also likely
to change if the treatment is effective. For all secondary
analyses, loss to follow up has been estimated at 10% at
eight weeks (of those surviving stroke at two weeks),
rising to 20% by twelve months.
Analysis
Statistical analysis is the responsibility of the CTRU stat-
istician and a final statistical analysis plan will be written
before any analysis is undertaken. All analyses will be
conducted on the ITT population defined as all partici-
pants randomised regardless of non-compliance with the
intervention. An overall two-sided 5% significance level
will be used for all endpoint comparisons.
Primary analysis of independent walking ability at eight
weeks post-randomisation (defined by a score of 7 or
above and who also answer ‘yes’ to item 7 on the RMI)
will be undertaken using logistic regression, while adjust-
ing for gender, type of stroke, centre and RMI at baseline.
For the primary outcome ITT analysis, it will be assumed
that patients who die or are lost to follow-up are
Table 1 Schedule of events
Assessment Timeline (months post randomisation)
Baseline 8 weeks
(+/- 7 days)
6 months
(+/- 14 days)
12 months
(+/- 14 days)
Eligibility and consent X
Baseline data (researcher/nurse completed from routinely collected data and ward staff)
Rivermead Mobility Index (professional perspective on patient’s ability for stratification) X
Past medical history X
Lesion location and type (CT scan) X
Montreal Cognitive Assessment (MoCA) X
Randomisation (within 42 days post stroke) X
Patient questionnaires (completed via researcher interview with patient)
Rivermead Mobility Index (patient’s perspective on ability) X X X X
ABILHAND scale X1 X X X
Nottingham Extended Activities of Daily Living Scale X1 X X X
General Health Questionnaire 12 X X X X
EQ-5D X X X X
Barthel Index (postal version but collected face to face) X X X X
MSK-SSP Manikin X1 X X X
Fatigue Assessment Scale X X X
Health Economics Resource Use Questionnaire X X X X
Carer questionnaires (Carer completed)
Caregiver Burden Scale X X X
EQ-5D X X X X
Health Economics Resource Use Questionnaire X1 X X X
Qualitative follow-up
Patient/therapist perspective regarding use of IMP X
Clinical follow-up data (researcher/therapist/nurse completed)
Treatment data (rehabilitation and drug compliance) X
Modified Rankin Scale X X
Montreal Cognitive Assessment (MOCA) X X X
Serious and non-serious adverse event monitoring Continuous reporting
as occur
New significant medical/surgical illness (e.g. for stroke, myocardial infarction, cancer,
fracture, elective surgical procedures)
X X
1Pre stroke.
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analysis will be undertaken to test the robustness of con-
clusions to this assumption. RMI will be analysed as a
continuous measure as part of secondary analyses.
Other outcome measures will be analysed for each
time point by regression models appropriate to the data
type. Such analyses will adjust for patient-level covariates
included as strata within the randomisation process in-
cluding gender, type of stroke, centre and RMI. Appro-
priate methods will be used to handle missing data.
Potential predictors (fatigue, depression, pain, medical
and surgical events, cognitive function, activities of daily
living, number of rehabilitation therapy sessions andnumber of tablets taken) of response to Co-careldopa
will be explored using baseline measurements taken for
primary and secondary outcomes. In addition, we plan
to model the relationship between potential moderator
and mediator variables and treatment effect.
A per-protocol analysis will be carried out to indicate
whether results are sensitive to the exclusion of patients
who violated the protocol.
The number of patients reporting a SAE (up to 30 days
after the last dose of treatment) and details of all SAEs
will be reported for each treatment group.
The Trial Statistician will be blinded to treatment
group allocation throughout the trial until the database
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Statistician, Supervising Trial Statistician, back-up Safety
Statistician and Safety Data Manager will have access to
unblinded treatment group allocation prior to final
analysis.
The primary within-trial economic analysis will be a
cost-utility analysis yielding cost per incremental quality-
adjusted life year (QALY). A secondary within-trial analysis
will estimate the incremental cost per patient achieving
independent walking (as determined by a score of ≥7 on
the RMI) at eight weeks post-randomisation for Co-
careldopa versus placebo. A decision-analytic model will
be developed to estimate the lifetime costs and effects
(QALYs) of the interventions and the resulting incre-
mental cost-effectiveness ratio (ICER) referenced to the
NHS willingness to pay per QALY gain threshold. Exten-
sive deterministic and probabilistic sensitivity analyses will
be conducted to estimate the level of uncertainty around
the results. QALY values will be based on EQ-5D utility
and the perspective of the analysis will be Health and
Personal Social Care.Data monitoring
Trial supervision includes a core Project Team, Trial
Management Group (TMG), a Trial Steering Committee
(TSC) and Data Monitoring and Ethics Committee
(DMEC). Only the DMEC will have access to unblinded
data prior to final analysis and, in strict confidence, re-
view unblinded adverse event data on a quarterly basis.
Data will be monitored for quality and completeness by
the CTRU. Missing data will be chased until it is received,
confirmed as not available or the trial is at analysis.Trial organisation and administration
The DARS trial is funded by the Efficacy and Mechan-
ism Evaluation (EME) programme (Grant reference
number 08/43/61). The trial is sponsored by the Univer-
sity of Leeds and was developed by the DARS trialists in
collaboration with the support of the UK Stroke Research
Network Rehabilitation Clinical Studies Group. The trial
is adopted by the UK Stroke Research Network and is sup-
ported in the delivery by the Stroke Research Network
staff. The trial is registered (ISRCTN99643613; EudraCT
Number: 2009-017925-20). The trial will be conducted in
accordance with the EU Clinical Trials Directive 2001/20/
EC and will be conducted in accordance with the UK
Medicines for Human Use (Clinical Trials) Amendment
Regulations 2006, the principles of good clinical practice
(GCP) in clinical trials, the NHS Research Governance
Framework, and through adherence to CTRU standard
operating procedures. Ethical approval has been obtained
through the UK National Research Ethics Service (ref 10/
H1005/6).Discussion
Stroke has a huge impact, leaving more than a third of
survivors with lasting disability. Rehabilitation remains
the cornerstone treatment within the NHS and the
current consensus suggests early rehabilitation interven-
tions are likely to be of greater benefit. Therefore, en-
hancing the effect of conventional physical rehabilitation
with L-dopa is likely to have greater impact when linked
to early stroke care through a stroke unit and through
community rehabilitation services. Co-careldopa provides
an exciting and important opportunity to manipulate
the brain’s pharmacological environment at a time
when physiological remodelling of the brain is occur-
ring through conventional rehabilitation treatments.
This not only has potential to enhance the effect of
conventional therapies but also new rehabilitation in-
terventions. Understanding the relationship between
pharmacologically primed neuroplasticity and practice
dependent neuroplasticity is of major scientific interest
in understanding how the brain adapts to injury. A key
aspect of this type of intervention is temporally linking
it to conventional rehabilitation treatments for people
with stroke. The dose and timing of the medication
within the trial design reflects current evidence on use
of L-dopa in this context (9, 11, 12, 13). This study is
the largest randomised controlled trial investigating the
use of Co-careldopa to improve functional outcomes in
acute stroke. If conclusive evidence of benefit is identi-
fied from this large trial, it is very likely that given the
low cost of L-dopa preparations it will be adopted
world-wide in stroke rehabilitation.
The clinical trial presented some implementation chal-
lenges that we have addressed (for example, pharmacoad-
herance; configuration of UK stroke services to allow
continuity of intervention; challenges to recruitment).
Pharmacoadherance: A key aspect of this study has
been to ensure that the drug is taken by the participant
at the correct time both in hospital and when the person
is at home. Stroke survivors may have significant residual
impairments, such as weakness, aphasia, visual disturb-
ance, cognitive problems and mood disorders, which may
affect their ability to comply with the medication/therapy
schedule. Non-adherence or partial adherence of research
participants can result in inconsistent study results.
There is no single effective approach and, therefore, a
multi-modal approach incorporating best available advice
from the Cochrane review [14] and guidance provided by
the American Psychological Society [15] has been used.
This approach includes provision of understandable infor-
mation sheets, reminders (for example, manual telephone
follow-up for those in the community) and involving
carers where appropriate. The available evidence suggests
that the greater the interaction with the patient, the more
likely the person is to adhere to the medication. This study
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is, prior to rehabilitation treatment). Mis-timing of medi-
cation is a common and important problem [16]. During
trial set-up processes, we involved 19 stroke survivors
in small group discussions about different aspects of
IMP labelling and packaging. Different examples of IMP
packaging, developed using UK National Patient Safety
Association guidance, were presented to the patient
group and preferences/opinions were obtained through
standardised questionnaires. We have used push-through
blister packs as they protect the study drug integrity. The
packs are appropriately labelled so that the study drug is
taken in relation to the rehabilitation sessions whether in
the community or in hospital. The package will serve as a
visual aid, encouraging patients to take the trial medica-
tion at the prescribed times and giving the patient the abil-
ity to recognize whether or not they have taken the
scheduled dose. Prescription information and educational
materials will be part of the medication’s packaging which
will also include an instructional area on the blister pack
itself; the outer carton of the package contains space for
dosing instructions, reminders and branding in large,
readable fonts. The nature of the optimal packaging and
ensuring maximum pharmacoadherance was designed in
collaboration with input from clinicians, pharmacy staff,
people with stroke and their families and the manufacturer
of IMP. This also includes design and implementation of
appropriate training for those dispensing the trial inter-
vention both in the hospital and when patients are self-
medicating at home.
Monitoring adherence is a key process issue. Therapy
staff, in conjunction with nursing staff if the participant
is an in-patient, are asked to complete an intervention
record for each participant which includes timing, ther-
apy duration and type and whether the trial medication
has been taken at the correct time. The research nurse
at each recruiting centre will collate adherence informa-
tion and complete Case Report Forms (CRFs) and send
them to the CTRU. We will also undertake pill count-
ing; even though it has limitations, it is suggested as a
standard for monitoring medication adherence in clin-
ical trials [17].
We have also developed a DVD for the participants/
carers to view in the hospital or their home environment
to provide an audio visual aid to supplement the Patient
Information Sheet. The DVD includes voice over explain-
ing trial processes, in particular, the therapy/IMP schedule,
safety issues and contact details. IMP/therapy schedule
compliance was also discussed with community therapists.
The patient feedback was incorporated into IMP pack-
aging to allow one handed opening and prompts for ad-
herence to IMP schedule. The DVD content is presented
in a manner accessible to patients with aphasia or hemi-
sensory neglect and uses graphics to illustrate abstractconcepts, such as randomisation. The DVD will be given
to trial participants as part of the recruitment information
pack.
A process has been implemented for the therapist (1)
to call the patient 45 minutes before the therapy session
to remind the patient to take their IMP and (2) to con-
duct a compliance check at each therapy session. Whilst
an inpatient, the rehabilitation staff will liaise with nurs-
ing staff to ensure that patients are administered the trial
medication prior to the rehabilitation treatments. Pack-
aging is also a determinant in improving compliance rates.
In the CRF for the study we have incorporated questions
about these aspects to investigate participant opinion in
the context of a clinical trial.
Configuration of UK stroke services: The English
National Stroke Strategy is intended to provide a quality
framework against which local services can secure im-
provements to stroke services and address health inequal-
ities relating to stroke over the next ten years; provide
advice, guidance and support for commissioners, strategic
health authorities, the voluntary sector and social care in
the planning, development and monitoring of services;
and inform the expectations of those affected by stroke
and their families by providing a guide to high-quality
health and social care services. An important aspect of
this strategy is the provision of early supported dis-
charge from an acute hospital-based stroke service for
people with moderate disability as a result of stroke.
The exact configuration of the services is not crucial as
long as the services are multidisciplinary and staff has
the right specialist skills and can provide intervention
without delay after discharge from hospital. A number
of stroke services across England have implemented this
aspect of the strategy. The configuration of these services
can vary between those services that have a dedicated
stroke-specific multidisciplinary team who provide on-
going rehabilitation in the person’s home to community
hospital facilities which provide ongoing rehabilitation
within an inpatient setting.
A key aspect of the design of the DARS trial is the rec-
ognition of the varied configuration of community stroke
rehabilitation services as well as a system for continuity
of provision of trial intervention after discharge from
hospital given that the length of stay in hospitals for
people with acute stroke is decreasing. The median
length of stay of people with acute stroke in hospital in
2010 was 9 days and mean was 19.5 days [18]. The de-
sign of this clinical trial ensures patients are able to con-
tinue the trial medication after discharge from hospital
to community. In the UK, community services are sep-
arate organisations to those of acute hospitals which
can complicate the implementation of clinical trials of
investigational medicinal products (CTIMPs) from a re-
search governance perspective.
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We anticipated to reach the target sample size by April
2014. Follow-up will continue for 12 months and we
expect to publish the results in late 2015. The trial will
be published in the NIHR Journals Library, which is
open access, free to view and indexed on several data-
bases including MEDLINE and the Cochrane Library.
The dissemination strategy includes presentation of the
primary results at relevant international stroke confer-
ences, peer-reviewed publications and presentations at
relevant stroke rehabilitation/neuroimaging conferences.
We will work with the Public and Patient Involvement
(PPI) representatives to develop lay reports to dissemin-
ate research findings to patient groups.
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